Kedokteran & Kesehatan editorial
Open AccessOA2024
Drug Resistance in Ovarian Cancer: From Mechanism to Clinical Trial
This review synthesizes the main mechanisms of drug resistance in ovarian cancer—abnormalities in transmembrane transport, DNA damage repair, signaling pathways, and epigenetic modifications—and highlights miRNAs as regulators. It also summarizes recent phase I/II clinical trials of novel drugs targeting these mechanisms.
Ling Wang; Xin Wang; Xue-Ping Zhu; Lin Zhong; Qing-Xiu Jiang; Ya Wang; Qin Tang; Qiao-Ling Li; Cong Zhang; Hai-Xia Wang; Dong-Ling Zou· Molecular Cancer· 2024· DOI 10.1186/s12943-024-01967-3
The core problem
Ovarian cancer remains the leading cause of gynecological cancer-related death. Drug resistance is the primary bottleneck in treatment, and the increasing use of novel drugs complicates the management of resistant disease. Traditional classification of resistance by drug type is inadequate; a mechanism-based understanding is needed. This review aims to consolidate knowledge on resistance mechanisms and link them to emerging clinical trials.
Innovation
The authors conducted a literature review of studies on drug resistance mechanisms in ovarian cancer, focusing on: abnormalities in transmembrane transport, alterations in DNA damage repair, dysregulation of cancer-associated signaling pathways, and epigenetic modifications (DNA methylation, histone modifications, noncoding RNA activity). They also examined the role of microRNAs (miRNAs), including 'epi-miRNAs' that modulate epigenetic regulators, and reviewed phase I/II clinical trials of novel drugs based on these mechanisms.
Introduction
Ovarian cancer remains the leading cause of gynecological cancer-related death. Drug resistance is the primary bottleneck in treatment, and the increasing use of novel drugs complicates the management of resistant disease. Traditional classification of resistance by drug type is inadequate; a mechanism-based understanding is needed. This review aims to consolidate knowledge on resistance mechanisms and link them to emerging clinical trials.
Why it matters
The authors propose that classifying drug resistance by mechanism rather than by drug type provides a more rational framework for developing combination therapies and overcoming cross-resistance. The regulatory role of miRNAs, particularly epi-miRNAs, offers potential targets for intervention. The review highlights the need for further clinical validation of mechanism-based therapies and suggests that understanding the interplay between genetic and epigenetic resistance mechanisms will be crucial for improving outcomes in ovarian cancer.
Who should read this
Pembaca Research Digest dan praktisi rumpun ini.
Opening member content…